The Exelon Clicker is a convenient and effective treatment option for patients with mild to moderate dementia of the Alzheimer's type and Parkinson's disease dementia. The transdermal patch provides a steady dose of rivastigmine, which has been shown to improve cognitive function and slow down the progression of dementia. While the patch may cause skin reactions and other adverse effects, these can be minimized by proper application and monitoring. Overall, the Exelon Clicker is a valuable treatment option for patients with dementia, and its use should be considered in conjunction with other therapies to optimize patient outcomes.
The efficacy of Exelon Clicker has been evaluated in several clinical trials. In a randomized, double-blind, placebo-controlled study, patients with Alzheimer's disease who received the Exelon Clicker patch showed significant improvements in cognitive function, as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) subscale. Similarly, in a study of patients with Parkinson's disease dementia, the Exelon Clicker patch was shown to improve cognitive function and functional ability. Exelon Clicker
The Exelon Clicker patch is available in two strengths: 4.6 mg/24 hours and 9.5 mg/24 hours. The recommended starting dose is 4.6 mg/24 hours, which can be increased to 9.5 mg/24 hours after a minimum of 4 weeks, based on patient response and tolerability. The patch should be applied to the upper outer arm, upper chest, or back once daily. The Exelon Clicker is a convenient and effective